Recursion Pharmaceuticals Reports Q1 2025 Results: AI-Driven Strategy Reshapes Pipeline and Partnerships

Recursion's AI-Driven Strategy Reshapes Drug Discovery Landscape

Recursion Pharmaceuticals (NASDAQ: RXRX), a leading clinical-stage TechBio company, has reported its first quarter 2025 financial results and business updates, showcasing the impact of its AI-driven approach on drug discovery and development 1

1

2

2

. The company's decade-long investment in artificial intelligence is now driving a data-led portfolio strategy, prioritizing high-potential programs to accelerate better treatments for patients.

Strategic Pipeline Adjustments

Recursion has implemented a focused R&D strategy, advancing a streamlined portfolio of over five clinical and preclinical programs in oncology and rare diseases 1

1

. This strategic shift has led to the deprioritization of three clinical programs and one preclinical program following a data-driven review. The company's Chief R&D Officer and Chief Commercial Officer, Najat Khan, emphasized that this portfolio evolution reflects Recursion's commitment to areas of high unmet need where they believe they can have the greatest impact 1

1

2

2

.

Key Program Updates

REC-4881 (MEK1/2) for Familial Adenomatous Polyposis (FAP)

Preliminary data from the Phase 1b/2 TUPELO study showed promising results:

• Median 43% reduction in polyp burden at week 13 (n=6 patients)
• 50% of patients achieved ≥1-point improvement in Spigelman stage
• Generally consistent safety profile with prior MEK1/2 inhibitors 1

  1

REC-7735 (PI3Kα H1047R) for Breast Cancer

• Candidate profiling ongoing with DC nomination expected in 2H25
• Showed dose-dependent tumor regression in preclinical models
• Potential for improved efficacy and tolerability compared to standard-of-care 1

  1

REV102 (ENPP1) for Hypophosphatasia (HPP)

• IND-enabling studies ongoing with Phase 1 initiation expected in 2H26
• Improved survival in early-onset HPP model and bone defects in late-onset model
• First-in-class potential for adult-onset HPP 1

  1

Partnership Milestones

Recursion's collaborations with major pharmaceutical companies have yielded significant progress:

1. Sanofi Collaboration:

   • Achieved fourth milestone, generating $7 million
   • Identified orally active small-molecule lead with best-in-class potential in autoimmune diseases
   • Total cash inflows of $130 million to date, with potential for over $300 million in additional milestone payments 1

     1

     2

     2

2. Roche and Genentech Collaboration:

   • Built five phenomaps from over one trillion iPSC-derived cells and 100 billion GI Oncology relevant cells
   • Integrated high-throughput screens with detailed cell measurements to inform AI/ML models
   • Focused on leveraging Recursion OS to identify novel programs in GI Oncology and Neuroscience 2

     2

Platform and Financial Updates

Recursion has implemented synergies and streamlined operations while maintaining core capabilities, extending its cash runway until mid-2027 1

1

. The company's CFO, Ben Taylor, highlighted the benefits of the recent business combination with Exscientia, allowing for more efficient operational goals and flexibility in uncertain market conditions 2

2

.

Looking Ahead

As Recursion continues to leverage its Recursion OS platform and AI capabilities, the company is poised to lead the transformative shift in drug discovery. With a focused portfolio, strategic partnerships, and a strong financial position, Recursion aims to decode biology and radically improve lives through its innovative TechBio approach 1

1

2

2

.